Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

Haemophilia

Volumn 21, Issue 3, 2015, Pages 320-329

  Villarrubia, R ^a   Oyaguez I ^a   Alvarez Roman M T ^b   Mingot Castellano, M E ^c   Parra, R ^d   Casado, M A ^a  

^a Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cost analysis; Haemophilia; Inhibitors; On demand; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; CONSULTATION; COST BENEFIT ANALYSIS; DRUG COST; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA A; HOSPITALIZATION; HUMAN; MEDICAL PROCEDURES; MUSCLE BLEEDING; PRIORITY JOURNAL; PROPHYLAXIS; SOFT TISSUE BLEEDING; SPAIN; COMPLICATION; HEMORRHAGE; IMMUNOLOGY; PREMEDICATION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DRUG COSTS; FACTOR VIIA; FACTOR VIII; HEALTH CARE COSTS; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES; MODELS, STATISTICAL; PREMEDICATION; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84928826079     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12681     Document Type: Article

References (45)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
2. Simpson ML, Valentino LA. Management of joint bleeding in hemophilia. Expert Rev Hematol 2012; 5: 459-68.
3. Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med 2012; 2012: 201271. doi:10.1155/2012/201271.
4. Naraine VS, Risebrough NA, Oh P et al. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia 2002; 8: 112-20.
5. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
6. Aznar JA, Lucía F, Abad-Franch L et al. Haemophilia in Spain. Haemophilia 2009; 15: 665-75.
7. Aznar JA, Abad-Franch L, Cortina VR, Marco P; Inherited bleeding disorders group from the Spanish Society of Thrombosis and Haemostasis. The National registry of haemophilia A and B in Spain: results from a census of patients. Haemophilia. 2009; 15: 1327-30.
8. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011; 9: 700-10.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
10. Gringeri A, Leissinger C, Cortesi PA et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43.
11. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
12. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
13. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
14. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5: 25-32.
15. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
16. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl. 6): 1-7.
17. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
18. Teitel J. Inhibitor economics. Semin Hematol 2006; 43(2 Suppl. 4): S14-7.
19. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
20. Feldman BM, Berger K, Bohn R et al. Haemophilia prophylaxis: how can we justify the costs? Haemophilia 2012; 18: 680-4.
21. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
22. Astermark J, Donfield SM, DiMichele DM et al.; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
23. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
24. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
25. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
26. Antunes SV, Tangada S, Stasyshyn O et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65-72.
27. Stasyshyn O, Antunes S, Mamonov V et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia 2014; 20: 644-50.
28. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
29. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
30. Escuriola Ettinngshausen C, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia. 2010;16:90-100.
31. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
32. Young G, Auerswald G, Jimenez-Yuste V et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012; 130: 864-70.
33. Ewenstein B, Giangrande P, Morfini M. Evaluation of FEIBA for prophylaxis in patients with inhibitors. Haemophilia 2004; 10: 113-6.
34. Cheng S, Chen Y, Chiang J. FEIBA prophylaxis in hemophilia A patient with inhibitors decreases bleeding episodes, improves joint function and enhance quality of life. Haemophilia 2006; 12: Abstract 14 PO 371.
35. Ewing NP, Pullens L, De Guzman C. Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis. J Thromb Haemost. 2007; 5: Abstract P-T.158.
36. Lambert T, Fressinaud E, Goudemand J, Rafowicz A. Can long-term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor? Haemophilia 2006; 12: Abstract 14 PO 399.
37. BotPlus 2.0.Consejo General de Colegios Oficiales de Farmacéuticos. Available at: https://botplusweb.portalfarma.com/botplus.aspx. Accessed October 23, 2013.
38. Oblikue - Database on costs and prices of the Spanish healthcare sector. Available at: http://www.oblikue.com/bddcostes/. Accessed October 23, 2013.
39. Konkle BA, Josephson NC, Nakaya Fletcher SM, Thompson AR. Hemophilia A. [updated 2011 Sep 22]. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle, 2000, 1993-2014. Available at http://www.ncbi.nlm.nih.gov/books/NBK1404/. Accessed on March 17, 2014.
40. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centers. Haemophilia 2007; 13: 502-7.
41. Di Minno MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2010; 16: e190-201.
42. Astermark J, Altisent C, Batorova A et al.; European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
43. Jiménez-Yuste V, Alvarez MT, Martín-Salces M et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
44. Zanon E, Iorio A, Rocino A et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia 2012; 18: 39-45.
45. Nuss R, Soucie JM, Evatt B; Hemophilia Surveillance System Project Investigators. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol 2001; 68: 37-42.